Aclaris Therapeutics Inc (fra:8AT) Share Price

Company Profile

Business description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Contact
701 Lee Road
Suite 103
WaynePA19087
USA
T: +1 484 324-7933
E: [email protected]
https://www.aclaristx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
73

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,905.80	11.30	-0.13%
CAC 40	7,740.48	70.78	-0.91%
DAX 40	25,111.26	260.49	-1.03%
Dow JONES (US)	52,867.98	11.89	0.02%
FTSE 100	10,656.46	68.57	-0.64%
HKSE	23,093.37	158.69	0.69%
NASDAQ	26,008.86	694.00	-2.60%
Nikkei 225	62,693.16	214.68	-0.34%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,663.43	0.00	0.00%
S&P/ASX 200	8,795.20	2.00	0.02%
SSE Composite Index	3,690.48	32.45	0.89%